Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

16th Sep 2009 17:25

RNS Number : 1933Z
ABCAM Plc
16 September 2009
 



For immediate release

16 September 2009

 ("Abcam" or "the Company")

Director's Dealings 

Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that the following transactions were undertaken by Directors of the Company on 16 September 2009:

Director

Number of 1 pence ordinary shares sold

Price per share sold (p)

Subsequent Beneficial Holding

Percentage of issued share capital following sale

David Cleevely

2,000,000

800

559,760

1.6%

Jonathan Milner

1,000,000

800

6,085,280

17.1%

Jim Warwick*

20,000

800

833,520

2.3%

*4,000 of these shares were sold by his wife Jane Dominey.

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeffrey Iliffe, Chief Financial Officer

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson / Stasa Filiplic

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUnited Kingdom, with offices in CambridgeMassachusettsUSA and TokyoJapan. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 52,000 products, most of which are antibodies, from over 250 suppliers and employs 237 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSQQLFFKKBFBBQ

Related Shares:

ABC.L
FTSE 100 Latest
Value8,275.66
Change0.00